MindImmune Caps Off a $30M Series A Round
MindImmune Caps Off a $30M Series A Round
Round marks major milestone for sister fund RightHill Ventures
MindImmune, a University of Rhode Island based company, has just capped a $30M Series A round. Funds will support the company through an IND and then into the clinic. MindImmune began in the George & Anne Ryan Institute for Neuroscience with CNS drug-discovery scientists and longtime collaborators Stevin Zorn, Ph.D., Frank Menniti, Ph.D., and Robert Nelson, Ph.D. leading the helm in both the lab and the classroom.
This round was lead by Dolby Family Ventures and in addition to RightHill Ventures included participation from Gates Frontier, Pfizer Ventures, and Foundation for a Better World. In 2016 Slater Technology Fund was the first money into MindImmune. Since then Slater and RightHill have backed MindImmune at every raise with this latest round marking two milestones for RightHill Ventures:
- The $1.45M raised through the SPV is the largest single round in RightHill’s history
- That commitment makes MindImmune the largest investment in RightHill's portfolio.
MindImmune Announces New CEO
Isaac Stoner
MindImmune CEO
"I feel fortunate to be leading this talented company as we advance an important first-in-class therapeutic into clinical development."
~ Stoner
Mr. Stoner brings more than 18 years of experience in life sciences entrepreneurship and company building to MindImmune. He most recently served as entrepreneur-in-residence at Slater Technology Fund and as an advisor and limited partner at KdT Ventures. From 2017 to 2025, he co-founded and led Octagon Therapeutics (a Slater portfolio comapny), serving as CEO for five years.
MindImmune's Novel Approach
What if plaques on the brain were not the whole story when it comes to Alzheimer's? What if cells from the blood stream were the catalyst that turned benign plaques harmful?
